CN Patent

CN110267964B — 作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物

Assigned to Bristol Myers Squibb Co · Expires 2022-05-03 · 4y expired

What this patent protects

本发明涉及具有下式I的化合物或其立体异构体或药学上可接受的盐，其中所有取代基如本文所定义，其可用于通过作用于Tyk‑2以引起信号转导抑制来调节IL‑12、IL‑23及/或IFNα。

USPTO Abstract

本发明涉及具有下式I的化合物或其立体异构体或药学上可接受的盐，其中所有取代基如本文所定义，其可用于通过作用于Tyk‑2以引起信号转导抑制来调节IL‑12、IL‑23及/或IFNα。

Drugs covered by this patent

Patent Metadata

Patent number
CN110267964B
Jurisdiction
CN
Classification
—
Expires
2022-05-03
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.